Company Filing History:
Years Active: 2013-2018
Title: The Innovative Contributions of Marina Bubis
Introduction
Marina Bubis is a prominent inventor based in Rehovot, Israel. She has made significant contributions to the field of biotechnology, particularly in the development of therapeutics and diagnostics. With a total of nine patents to her name, her work focuses on novel drug targets that have the potential to revolutionize cancer treatment and immunotherapy.
Latest Patents
One of her latest patents involves polypeptides and polynucleotides that serve as drug targets for producing drugs and biologics. This invention relates to a novel target for the production of immune and non-immune based therapeutics and for disease diagnosis. More specifically, it provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32, or FXYD3 antigens, which are predicted co-stimulatory family members. These antigens are differentially expressed in various cancers, including lung cancer, ovarian cancer, and colon cancer. The invention also discusses the use of these antibodies for modulating B7 costimulation and related therapies, such as the treatment of autoimmunity. Furthermore, it highlights the discovery of extracellular domains of these antigens and their variants, which are suitable targets for immunotherapy, cancer therapy, and drug development.
Career Highlights
Marina has worked with notable companies in the biotechnology sector, including Compugen Ltd. and Macrocure Ltd. Her experience in these organizations has contributed to her expertise in developing innovative therapeutic solutions.
Collaborations
Throughout her career, Marina has collaborated with talented individuals such as Amir Toporik and Amit Novik. These partnerships have enhanced her research and development efforts, leading to groundbreaking advancements in her field.
Conclusion
Marina Bubis is a trailblazer in the realm of biotechnology, with her innovative patents paving the way for new therapeutic approaches to cancer and autoimmune diseases. Her contributions are poised to make a lasting impact on the medical community and patient care.